Vistagen Therapeutics, Inc.

NasdaqCM:VTGN Stok Raporu

Piyasa değeri: US$84.1m

Vistagen Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Vistagen Therapeutics has a total shareholder equity of $104.8M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $113.5M and $8.7M respectively.

Anahtar bilgiler

0%

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranın/a
NakitUS$108.36m
EşitlikUS$104.80m
Toplam yükümlülüklerUS$8.75m
Toplam varlıklarUS$113.55m

Son finansal sağlık güncellemeleri

Here's Why We're Not Too Worried About VistaGen Therapeutics' (NASDAQ:VTGN) Cash Burn Situation

Apr 10
Here's Why We're Not Too Worried About VistaGen Therapeutics' (NASDAQ:VTGN) Cash Burn Situation

VistaGen Therapeutics (NASDAQ:VTGN) Is In A Strong Position To Grow Its Business

Jun 07
VistaGen Therapeutics (NASDAQ:VTGN) Is In A Strong Position To Grow Its Business

Recent updates

VistaGen to proceed with phase 3 anxiety nasal spray trial following interim analysis

Sep 08

VistaGen drops 80% as late-stage study for anxiety therapy fails

Jul 22

Here's Why We're Not Too Worried About VistaGen Therapeutics' (NASDAQ:VTGN) Cash Burn Situation

Apr 10
Here's Why We're Not Too Worried About VistaGen Therapeutics' (NASDAQ:VTGN) Cash Burn Situation

VistaGen Therapeutics added to Russell 2000 Index

Jun 16

VistaGen Therapeutics (NASDAQ:VTGN) Is In A Strong Position To Grow Its Business

Jun 07
VistaGen Therapeutics (NASDAQ:VTGN) Is In A Strong Position To Grow Its Business

VistaGen initiates late-stage trial of PH94B in social anxiety disorder

May 26

VistaGen names new chief commercial officer

May 04

How Does VistaGen Therapeutics' (NASDAQ:VTGN) CEO Salary Compare to Peers?

Feb 16
How Does VistaGen Therapeutics' (NASDAQ:VTGN) CEO Salary Compare to Peers?

VistaGen Therapeutics regains Nasdaq listing compliance

Jan 06

VistaGen Therapeutics slumps in after hours trade on underwritten public offering

Dec 17

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: VTGN's short term assets ($110.8M) exceed its short term liabilities ($6.2M).

Uzun Vadeli Yükümlülükler: VTGN's short term assets ($110.8M) exceed its long term liabilities ($2.5M).


Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: VTGN is debt free.

Borcun Azaltılması: VTGN has no debt compared to 5 years ago when its debt to equity ratio was 4.3%.


Bilanço


Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: VTGN has sufficient cash runway for more than 3 years based on its current free cash flow.

Tahmini Nakit Akışı: VTGN has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 22.1% each year.


Sağlıklı şirketleri keşfedin